Agenus, Inc. (AGEN)
7.67
-0.42
(-5.19%)
USD |
NASDAQ |
Aug 24, 16:00
7.67
0.00 (0.00%)
After-Hours: 20:00
Agenus EPS Diluted (Quarterly) : -0.0146 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.0146 |
| March 31, 2026 | 1.023 |
| December 31, 2025 | -0.301 |
| September 30, 2025 | 1.944 |
| June 30, 2025 | -0.9962 |
| March 31, 2025 | -1.035 |
| December 31, 2024 | -2.04 |
| September 30, 2024 | -3.083 |
| June 30, 2024 | -2.523 |
| March 31, 2024 | -3.041 |
| December 31, 2023 | -2.350 |
| September 30, 2023 | -3.293 |
| June 30, 2023 | -3.931 |
| March 31, 2023 | -4.308 |
| December 31, 2022 | -4.80 |
| September 30, 2022 | -3.784 |
| June 30, 2022 | -3.356 |
| March 31, 2022 | -3.746 |
| December 31, 2021 | -5.104 |
| September 30, 2021 | 14.47 |
| June 30, 2021 | -7.478 |
| March 31, 2021 | -5.364 |
| December 31, 2020 | -3.841 |
| September 30, 2020 | -5.606 |
| June 30, 2020 | -5.621 |
| Date | Value |
|---|---|
| March 31, 2020 | -6.167 |
| December 31, 2019 | -4.369 |
| September 30, 2019 | -6.616 |
| June 30, 2019 | -7.529 |
| March 31, 2019 | 2.484 |
| December 31, 2018 | -8.00 |
| September 30, 2018 | -5.771 |
| June 30, 2018 | -4.80 |
| March 31, 2018 | -10.60 |
| December 31, 2017 | -7.00 |
| September 30, 2017 | -7.40 |
| June 30, 2017 | -6.40 |
| March 31, 2017 | -3.60 |
| December 31, 2016 | -6.00 |
| September 30, 2016 | -9.40 |
| June 30, 2016 | -6.60 |
| March 31, 2016 | -7.40 |
| December 31, 2015 | -3.60 |
| September 30, 2015 | -3.20 |
| June 30, 2015 | -10.60 |
| March 31, 2015 | -5.60 |
| December 31, 2014 | -8.20 |
| September 30, 2014 | -2.60 |
| June 30, 2014 | -2.40 |
| March 31, 2014 | -0.20 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Iovance Biotherapeutics, Inc. | -0.1051 |
| Novavax, Inc. | -0.3244 |
| Fate Therapeutics, Inc. | -0.2505 |
| Amgen, Inc. | 4.366 |
| Anika Therapeutics, Inc. | 0.2412 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -0.567M |
| Revenue (Quarterly) | 34.52M |
| Total Expenses (Quarterly) | 35.07M |
| Enterprise Value | 609.42M |
| Gross Profit Margin (Quarterly) | 98.50% |
| Profit Margin (Quarterly) | -1.64% |
| Earnings Yield | 34.56% |
| Operating Earnings Yield | 12.66% |
| Normalized Earnings Yield | 13.01 |